2 years ago

Mesenbio Secures £1.4 Million to Advance Stem Cell Treatment for Arthritis

  • Mesenbio, a University of York spin-out, has raised £1.4 million in funding to develop a novel treatment for arthritis using engineered human stem cells

  • The round was led by DSW Ventures and NG Bio, with additional funding from Innovate UK

  • The investment will enable the company to hire new staff, develop pilot manufacturing processes, conduct pre-clinical studies, and prepare for clinical trials

  • The treatment, based on nano-sized messengers from engineered stem cells, aims to reduce inflammation and regenerate damaged tissue.

      • ProblemHealthcare

      "Rheumatoid arthritis is a debilitating disease affecting nearly half a million people in the UK alone, causing painful inflammation in the joints."

      Solution

      "Mesenbio is developing a novel treatment for arthritis using engineered human stem cells that act as nano-sized messengers to curb inflammation and regenerate damaged tissue."

      Covered on